{"id":"https://openalex.org/W2017296183","doi":"https://doi.org/10.1002/cncr.11424","title":"Treatment of Philadelphia chromosome\u2013positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon\u2010alpha\u20102b and low\u2010dose cytosine arabinoside","display_name":"Treatment of Philadelphia chromosome\u2013positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon\u2010alpha\u20102b and low\u2010dose cytosine arabinoside","publication_year":2003,"publication_date":"2003-05-29","ids":{"openalex":"https://openalex.org/W2017296183","doi":"https://doi.org/10.1002/cncr.11424","mag":"2017296183","pmid":"https://pubmed.ncbi.nlm.nih.gov/12784336"},"language":"en","primary_location":{"id":"doi:10.1002/cncr.11424","doi":"https://doi.org/10.1002/cncr.11424","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.11424","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11424","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11424","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061026876","display_name":"Guillermo Garcia\u2010Manero","orcid":"https://orcid.org/0000-0002-3631-2482","observed_orcids":["https://orcid.org/0000-0002-3631-2482"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Guillermo Garcia\u2010Manero","raw_affiliation_strings":["Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA. ggarciam@mdanderson.org","Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA. ggarciam@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Moshe Talpaz","raw_affiliation_strings":["Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer, Houston, Texas","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061285204","display_name":"Francis Joseph Giles","orcid":"https://orcid.org/0000-0002-6919-0231","observed_orcids":["https://orcid.org/0000-0002-6919-0231"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francis J. Giles","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge Cortes","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046097970","display_name":"Stefan H Faderl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stefan Faderl","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102743501","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0003-3386-6540","observed_orcids":["https://orcid.org/0000-0003-3386-6540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan O'Brien","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038307470","display_name":"Deborah Ann Thomas","orcid":"https://orcid.org/0000-0002-2656-343X","observed_orcids":["https://orcid.org/0000-0002-2656-343X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah Thomas","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109262636","display_name":"Mary Beth Rios","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Beth Rios","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103441872","display_name":"Jianquin Shan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jianquin Shan","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","University of Texas MD Anderson Cancer Center"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"University of Texas MD Anderson Cancer Center","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028845635","display_name":"Alessandra Ferrajoli","orcid":"https://orcid.org/0000-0001-9547-4193","observed_orcids":["https://orcid.org/0000-0001-9547-4193"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alessandra Ferrajoli","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Wierda","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop M. Kantarjian","raw_affiliation_strings":["Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Leukemia, The University of Texas M. D. Anderson Cancer, Houston, Texas","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5061026876"],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":1.1935,"has_fulltext":true,"cited_by_count":10,"citation_normalized_percentile":{"value":0.78678699,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"97","issue":"12","first_page":"3010","last_page":"3016"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/philadelphia-chromosome-positive-chronic-myelogenous-leukemia","display_name":"Philadelphia chromosome-positive chronic myelogenous leukemia","score":0.9570000171661377},{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.7960000038146973},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9470000267028809},{"id":"https://openalex.org/keywords/low-dose-cytarabine","display_name":"low-dose cytarabine","score":0.8539999723434448},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/complete-hematologic-response","display_name":"complete hematologic response","score":0.7590000033378601},{"id":"https://openalex.org/keywords/cytogenetic-response","display_name":"cytogenetic response","score":0.9319999814033508},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.7409999966621399},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9739999771118164},{"id":"https://openalex.org/keywords/fatigue","display_name":"fatigue","score":0.5899999737739563},{"id":"https://openalex.org/keywords/neurologic-toxicity","display_name":"neurologic toxicity","score":0.828000009059906},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.5950000286102295}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8460735082626343},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.686854362487793},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.6483756899833679},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.6385304927825928},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6311739087104797},{"id":"https://openalex.org/C2778041864","wikidata":"https://www.wikidata.org/wiki/Q180983","display_name":"Cytarabine","level":3,"score":0.6065059304237366},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6001288294792175},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5609909892082214},{"id":"https://openalex.org/C54400483","wikidata":"https://www.wikidata.org/wiki/Q1793202","display_name":"PEG ratio","level":2,"score":0.49066030979156494},{"id":"https://openalex.org/C2778904597","wikidata":"https://www.wikidata.org/wiki/Q1129111","display_name":"Philadelphia chromosome","level":4,"score":0.44921189546585083},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4259151220321655},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3660385310649872},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3148934841156006},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.22755515575408936},{"id":"https://openalex.org/C138626823","wikidata":"https://www.wikidata.org/wiki/Q916504","display_name":"Chromosomal translocation","level":3,"score":0.08598917722702026},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.06217813491821289},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cncr.11424","doi":"https://doi.org/10.1002/cncr.11424","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.11424","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11424","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},{"id":"pmid:12784336","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12784336","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1002/cncr.11424","doi":"https://doi.org/10.1002/cncr.11424","is_oa":true,"landing_page_url":"https://doi.org/10.1002/cncr.11424","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.11424","source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.75,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2017296183.pdf","grobid_xml":"https://content.openalex.org/works/W2017296183.grobid-xml"},"referenced_works_count":18,"referenced_works":["https://openalex.org/W1430390330","https://openalex.org/W1602584478","https://openalex.org/W1799579309","https://openalex.org/W1862517694","https://openalex.org/W1966541023","https://openalex.org/W1985269587","https://openalex.org/W1989333836","https://openalex.org/W2011474502","https://openalex.org/W2026261593","https://openalex.org/W2048740168","https://openalex.org/W2049098874","https://openalex.org/W2065225927","https://openalex.org/W2103072940","https://openalex.org/W2122797075","https://openalex.org/W2242105263","https://openalex.org/W2329648702","https://openalex.org/W2337277825","https://openalex.org/W2528809503"],"related_works":["https://openalex.org/W1985269587","https://openalex.org/W2122797075","https://openalex.org/W2261675623","https://openalex.org/W1901923962","https://openalex.org/W2026875692","https://openalex.org/W2312828242","https://openalex.org/W2020348444","https://openalex.org/W2131656137","https://openalex.org/W2562089111","https://openalex.org/W2078051582"],"abstract_inverted_index":{"BACKGROUND:":[0],"To":[1],"evaluate":[2],"the":[3,43,65,76,120,217],"activity":[4,178],"and":[5,47,101,152,159,167,179,196,203],"toxicity":[6,154,180,210],"of":[7,15,45,57,83,91,103,117,132,175,182,201,224],"weekly":[8,63,166],"Schering":[9],"54301,":[10],"a":[11,86,94,106,114],"polyethylene":[12],"glycol":[13],"formulation":[14],"interferon-":[16],"alpha-2b":[17],"(PEG-IFN-alpha-2b),":[18],"with":[19,25,33,42,194,213],"cytosine":[20],"arabinoside":[21],"(ara-C)":[22],"in":[23,64,75,130,190,211,226],"patients":[24,32,68,84,92,104,133,192,212],"chronic":[26],"myelogenous":[27],"leukemia":[28],"(CML).":[29],"METHODS:":[30],"Seventy-six":[31],"Philadelphia":[34],"chromosome":[35],"(Ph)-positive":[36],"early":[37],"chronic-phase":[38,214],"CML":[39,215],"were":[40,163],"treated":[41,193],"combination":[44,184,200,228],"PEG-IFN-alpha-2b":[46,58,158,202,225],"ara-C":[48,160,204],"(10":[49],"mg":[50,169],"daily":[51],"subcutaneously":[52],"[s.c.]).":[53],"The":[54,156,177,199,221],"starting":[55],"dose":[56,145,218,223],"was":[59,70,125,128,185],"6":[60],"microg/kg":[61,74,165,232],"s.c.":[62],"first":[66],"24":[67],"but":[69,207],"reduced":[71],"to":[72,135,187],"4.5":[73],"next":[77],"52":[78],"patients.":[79],"RESULTS:":[80],"Overall,":[81],"73%":[82],"had":[85,93,105],"complete":[87,107],"hematologic":[88],"response,":[89],"35%":[90],"major":[95],"cytogenetic":[96,108],"response":[97,109],"(Ph":[98,110],"<":[99],"35%),":[100],"21%":[102],"=":[111],"0%).":[112],"With":[113],"median":[115,157],"follow-up":[116],"19":[118],"months,":[119],"estimated":[121],"2-year":[122],"survival":[123],"rate":[124],"89%.":[126],"Therapy":[127],"discontinued":[129],"24%":[131],"due":[134],"Grade":[136],"III-IV":[137],"toxicity.":[138],"Frequent":[139],"severe":[140],"side":[141],"effects":[142],"that":[143],"required":[144],"reductions":[146],"included":[147],"neutropenia":[148],"(49%),":[149],"fatigue":[150],"(43%),":[151],"neurologic":[153],"(17%).":[155],"doses":[161],"delivered":[162],"3":[164,231],"7.5":[168],"daily,":[170],"respectively,":[171],"at":[172,216],"12":[173],"months":[174],"therapy.":[176],"profiles":[181],"this":[183],"similar":[186],"those":[188],"observed":[189],"historical":[191],"IFN-alpha":[195],"cytarabine.":[197],"CONCLUSIONS:":[198],"is":[205,230],"active":[206],"has":[208],"significant":[209],"schedule":[219],"used.":[220],"recommended":[222],"future":[227],"studies":[229],"or":[233],"less.":[234]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2016-06-24T00:00:00"}